

TABLE OF CONTENTS

February 1, 2010

No. 2174

BUSINESS

- 1 Cymbalta to Drive Shionogi's Business in Mid-Term: Ms Sawada
 - New PK Study for S-2367 to Begin in 1st Half of 2010
- 2 Takeda to More Actively Develop Business in Emerging Markets: President Hasegawa
- 3 Banyu, Schering-Plough to Copromote 7 Products in Preparation for Merger
 - Copromotion to Boost Sales of Januvia
- 3 New Pricing System to Dramatically Change Industry Landscape: Mr Sakai of Credit Suisse
- 4 Change Wholesalers' Margin Structure to Avoid Over-competition: Mr Kimura
- 5 JPMA to Present Proposals for Industry Promotion
- 5 **BUSINESS NEWS IN BRIEF**
 - Teva-Kowa Acquires 2/3 of Taisho Pharm's Shares
 - Sciele Pharma Renamed Shionogi Pharma
 - Kyowa Kirin Revises Business Forecasts Downward
 - Iwaki Posts Net Losses Two Years in a Row
- 6 **Commentary**
 - New Pricing System to Make e-Detailing More Important

REGULATORY

- 8 29 Products Approved Including Japan's 1st GLP-1 Analogue
 - Japan's 1st GLP-1 Analogue Victoza: Novo Nordisk
 - Combination of ARB + Ca Blocker Rezaltas: Daiichi Sankyo
 - Higher-Strength Metformin Preparation Metgluco Tab 250 mg: DSP
 - Antidepressant Cymbalta: Shionogi
 - Xalacom for Glaucoma: Pfizer
 - Sugammadex for Reversal of Neuromuscular Blockade: Schering-Plough
 - Anti-Emetic Aloxi: Taiho
 - "Emergency Approval" for H1N1 Vaccine Arepanrix: GSK
 - BI-Sifrol as Japan's First Drug for RLS: NBI
 - Remicade for Psoriasis: MTPC
 - Humira for Psoriasis: Abbott, Eisai
 - Humira, Remicade to Be Excluded from DPC Payment When Used for Psoriasis

- 11 Novartis Again Obtains Approval for 4 Products at the Same Time
- 12 Anti-Flu Agent Rapiacta Included in NHI Price List
 - Shionogi to Conduct 4 Post-Marketing Studies for Rapiacta
- 13 *Koroshō* to Ask Companies to Comment on the Need for Listed Unapproved Drugs
- 13 New Premium to Allow *Chuikyo* to Interfere with Company Management: Prof. Tsutsumi
- 14 New Premium to Make Drugs More Liable to Re-Pricing: Mr Nishiyama
- 14 **REGULATORY NEWS IN BRIEF**
 - Advate 2000 for Hemophilia A: Baxter
- 15 Overview of Premium for Development of New Drugs to Be Introduced in April

R&D

- 19 IP Forum Focuses on Open Innovations
- 19 GLP-1 Analogues to Be Recommended for Severe DM

GENERICS

- 20 NIHS's Working Group Finds No Problems with Generics of 9 APIs
- 20 **GENERICS NEWS IN BRIEF**
 - EPO's Biosimilar Approved: JCR, Kissei
 - JGA President Expresses Hope for the New Pricing System

Survey

- 21 **Survey**
 - High Out-of-Pocket Expenses Cited by 38.4% of Households Not Seeing Doctor

Statistics

- 21 **Statistics**
 - Ethical Drugs Show Double-Digit Growth for the First Time in FY2009: Crecon

SELF-MEDICATION

- 22 JSMI Recommends 29 More APIs for Switching to OTC Status

MEDICAL FACILITIES & NURSING CARE

- 22 Notification Issued for Proper Use of Afinitor
- 23 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
 - Bendamustine Added to NCCN GLs as First-Line Therapy: SymBio
 - Greater Importance Put on Surgery in Insurance Coverage